Michael L. Lipton

https://assets.montefioreeinstein.org/profiles/images/Lipton_Michael_MD_420x504.jpg

First Name

Michael

Last Name

Lipton

NPI

1366535502

Faculty ID

148

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><strong>Michael L. Lipton, M.D., Ph.D., F.A.C.R.</strong><br />Dr. Lipton, a neuroradiologist and neuroscientist, is Associate Director of the Gruss Magnetic Resonance Research Center at Einstein and &nbsp;Medical Director of MRI Services for Montefiore Health, both in New York. He divides his professional time between the clinical practice of neuroradiology, teaching and research. Dr. Lipton&rsquo;s research broadly addresses the use of advanced noninvasive imaging technology to reveal heretofore-inaccessible substrates of brain dysfunction, particularly in the realms of behavior and cognition. More specifically, his research program has focused for nearly a decade on detecting and characterizing the effects of mild brain injury (AKA concussion). Specific areas of emphasis at present include the understanding of inter-individual differences in the manifestations of brain injury and the cumulative effects of repetitive subconcussive injury in sports. Dr. Lipton&rsquo;s work on the impact of subconcussive &ldquo;heading&rdquo; on brain structure and function in amateur soccer players, funded by the Dana Foundation and the National Institutes of Health, has been reported extensively in the press worldwide.</p>

Research Areas

Research Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<p>Dr. Lipton develops and applies advanced quantitative MRI to enhance characterization of brain disease in patients with persistent symptoms related to traumatic brain injury and other disorders that are not adequately visualized using conventional imaging approaches</p>

Research Focus

<p>Dr. Lipton applies advanced imaging technology to characterize the effects of trauma on behavior and cognition. His work on repeated subconcussive head impacts in soccer players has been reported extensively in the press worldwide.</p>

Elsevier Profile

Biography

<p>Michael L. Lipton, MD, PhD, FACR, is the Medical Director of MRI Services and an Attending Radiologist at Montefiore. He is also a Professor of Radiology, Psychiatry and Behavioral Sciences at our Albert Einstein College of Medicine. Dr. Lipton has been a member of the Montefiore team since 1997, with a clinical focus on developing advanced quantitative MRI to enhance characterization of brain diseases. He works primarily with patients who suffer persistent symptoms related to traumatic brain injury and other disorders that are not easily identified with conventional imaging approaches. </p><p>Dr. Lipton received his Doctor of Medicine from Boston University in 1990. He continued his studies by attending our Albert Einstein College of Medicine, where he received his Master of Science with Distinction and his Doctor of Philosophy in Neuroscience. His postgraduate training began with an internship in internal medicine at Brookdale Hospital Medical Center completed in 1991. Over 5 years, Dr. Lipton completed a residency and chief residency in diagnostic radiology, followed by a 2-year fellowship in neuroradiology at Montefiore, completing his postgraduate training in 1997. </p><p>Dr. Lipton has completed substantial research on repeated subconcussive head impacts in sports, particularly in soccer players. His work on this topic has been reported on extensively in the press worldwide. Dr. Lipton?s other research focuses mainly on the brain and has been shared in a number of presentations internationally, as well as published in numerous books and papers. </p><p>In 2017, Dr. Lipton received the Distinguished Investigator Award from the Academy of Radiology and Biomedical Imaging Research. Dr. Lipton is board certified by the American Board of Radiology, is a Fellow of the American College of Radiology and is a member of numerous professional societies, including the the American Medical Association, and the American Society of Neuroradiology. </p>

Is Open Scheduling

Off

Shiu M. Young

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Shiu

Last Name

Young

NPI

1467742726

Faculty ID

14110

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5826

Is Open Scheduling

Off

Michael Yee

https://assets.montefioreeinstein.org/profiles/images/13771-michael-yee.jpg

First Name

Michael

Last Name

Yee

NPI

1699971085

Faculty ID

13771

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5456

Is Open Scheduling

Off

Melissa Yao

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/d735b9a0-1a58-11ed-807c-9ff3b65d803d.jpg

First Name

Melissa

Last Name

Yao

NPI

1083870182

Faculty ID

12972

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<p>Routine and Complex Cataract Surgery</p><p>Medical and Surgical Treatment of Glaucoma</p><p>Comprehensive Ophthalmology</p>

Research Focus

<p>Glaucoma</p><p>Resident Education</p>

Elsevier Profile

EMR ID

5539

Biography

<p>Wen-Jeng M. Yao, MD, is an Attending Physician and Associate Professor in Ophthalmology at Montefiore Einstein. Her clinical focus is on routine and complex cataract surgery, medical and surgical treatment of glaucoma, and comprehensive ophthalmology. She enjoys establishing long-lasting relationships with her patients, delivering the highest quality clinical and surgical care in ophthalmology, and teaching residents who are training to become future ophthalmologists.</p><p>After receiving her Bachelor of Arts degree at Cornell University, Dr. Yao attended Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, earning her Doctor of Medicine in 2006. She began her postdoctoral training with a yearlong internship at Saint Peters University Hospital, followed by her residency in ophthalmology at George Washington University in 2010. In 2011, she completed her surgical glaucoma fellowship at Columbia Presbyterian Hospital.</p><p>Dr. Yao&rsquo;s research interests involve identifying epidemiological associations of glaucoma and advancing surgical and laser techniques for glaucoma therapy. Her work has been shared through peer-reviewed journals, book chapters, abstracts and poster presentations.</p><p>Dr. Yao is board certified and is a member of the American Academy of Ophthalmology and the American Glaucoma Society. She was listed as a Castle Connelly Top Doctor in 2021, 2022 and 2023.</p>

Is Open Scheduling

Off

Daniel A. Weiser

https://assets.montefioreeinstein.org/profiles/images/Weiser_Daniel_MD_2x.jpg

First Name

Daniel

Last Name

Weiser

NPI

1225239700

Faculty ID

13846

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><span style="text-decoration: underline;"><strong>Childhood cancer research laboratory</strong></span></p>
<p>Our laboratory is focused on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. In such patients with typically incurable cancer, we are striving to identify new approaches to and types of treatment. We have multiple ongoing projects:</p>
<p><strong>+ Identification of biologic drivers of ultra-high-risk neuroblastoma</strong>. Neuroblastoma is one of the most common and deadly childhood cancers. Despite intensive research, there are limited therapeutic strategies for patients with <em>de novo </em>chemotherapy resistance that leads to particularly poor outcomes. We have been studying neuroblastoma since 2009 and are identifying additional biologic drivers of highly lethal tumors.</p>
<p>We compare tumor features from patients with early death from tumor progression compared to those with a maintained complete response. We assess unique histo-morphologic and proteomic features and computationally integrate these data with genomic and transcriptomic datasets to develop a combined predictor of primary refractory disease. Patients with this entity require non-standard and/or intensified treatment. Oncogenic drivers are being characterized in the lab which will facilitate strategies for novel pharmacologic intervention.</p>
<p><strong>+ Characterization of neuroblastoma development from neural crest cells</strong>.&nbsp; We are studying pathways and interactions that results in uncontrolled cell proliferation early in neuroblastoma development with an ultimate goal of identifying new targets and approaches for pharmacologic intervention.</p>
<p><strong>+ Evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma</strong>.&nbsp; With expected outcomes lagging behind those of more common childhood cancers, children with neuroblastoma require new approaches to treatment. Our lab works with multiple international clinical and research consortium groups to perform preclinical studies that substantiate human clinical trials.&nbsp;</p>
<p><strong>+ Detection of circulating tumor DNA in osteosarcoma</strong>. With no reliable non-invasive approach for disease monitoring during and after treatment, we are applying cutting edge next-generation sequencing approaches to identify solid tumors with a blood-based &ldquo;liquid&rdquo; biopsies. This will allow clinicians to assess tumor responsiveness to chemotherapy and predict likelihood of recurrence.</p>
<p><strong>+ Assessment of accelerated aging using miRNA-seq in survivors of childhood cancer</strong>. Chemotherapy has many untoward effects on healthy cells and leads to many signs of accelerated aging in children treated for cancer. Using a known microRNA &ldquo;aging&rdquo; signature discovered at Albert Einstein College of Medicine, we are studying what causes this phenotype in childhood cancer, with a goal of offering improved intervention to minimize long-term toxicity of treatment.</p>
<p><strong><span style="text-decoration: underline;">Physician Summary</span></strong></p>
<p>Daniel A. Weiser, MD, is board-certified in pediatric hematology/oncology with clinical expertise in neuroblastoma and other tumors of the adrenal glands, kidneys, liver, and gonads. He is the medical director of the intra-abdominal solid tumor program at the Children&rsquo;s Hospital at Montefiore and brings together a highly specialized multi-disciplinary care team to provide comprehensive treatment for diverse pediatric malignancies. In addition, Dr. Weiser directs a childhood cancer research laboratory that focuses on the identification of new targeted agents for cancer therapy, especially in the treatment of rare and aggressive malignancies such as neuroblastoma. His research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise for improving management of all patients with solid tumors.</p>
<p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children&rsquo;s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Advances in Neuroblastoma Research Association (ANRA), National Pediatric Cancer Foundation (NPCF), and the American Academy of Pediatrics (AAP). He has received numerous awards including the Brigid Leventhal Special Merit Award from ASCO and the Conquer Cancer Foundation, and a prestigious K12 from the National Cancer Institute for the training of the next generation of physician-scientists in pediatric cancer. Dr. Weiser is actively involved in teaching and mentorship of trainees, and takes great pride in providing advanced and compassionate care to his patients and their families.</p>
<p><strong>Clinical Expertise</strong></p>
<ul>
<li>Neuroblastoma (adrenal tumors)</li>
<li>Wilms tumor (renal tumors)</li>
<li>Hepatoblastoma (liver tumors)</li>
<li>Germ cell tumors (including testicular and ovarian tumors)</li>
<li>Thyroid and other rare tumors</li>
<li>Experimental therapeutics</li>
<li>Cancer genetics and biomarkers</li>
</ul>
<p><strong>Board Certifications</strong></p>
<ul>
<li>Pediatrics</li>
<li>Pediatric Hematology/Oncology</li>
</ul>
<p><strong>Professional Education</strong></p>
<ul>
<li>M.D. &ndash; Stony Brook University, NY</li>
<li>Residency &ndash; Children&rsquo;s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Chief Residency &ndash; Children&rsquo;s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Fellowship &ndash; The Children&rsquo;s Hospital of Philadelphia, PA</li>
</ul>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

DR. Weiser's clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma, and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers.&nbsp;

Research Focus

Dr. Weiser&rsquo;s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser&rsquo;s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others.

Elsevier Profile

EMR ID

5755

Biography

<p>Daniel A. Weiser, MD, is a Medical Director of the Intra-abdominal Solid Tumor Program in the Pediatrics Hematology/Oncology department at Children&rsquo;s Hospital at Montefiore. He is also Associate Professor in the Pediatrics and Genetics departments at the Albert Einstein College of Medicine. His clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers. Dr. Weiser is actively involved in teaching and mentorship of trainees and takes great pride in his active participation in patient care.</p><p>Dr. Weiser received his Bachelor of Science in Neurobiology in 1995 at Haverford College, PA. In 2004, he received his Doctor of Medicine at Stony Brook University School of Medicine, NY. He is currently earning his Master of Science in Translational Research at the University of Pennsylvania. He began a residency in Pediatrics at the New York-Presbyterian, Columbia University in 2007. Dr. Weiser then completed a three-year fellowship in Pediatric Hematology/Oncology at The Children&rsquo;s Hospital of Philadelphia. </p><p>Dr. Weiser&rsquo;s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser&rsquo;s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others. His research has been published in many reviewed journals. </p><p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children&rsquo;s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and the American Academy of Pediatrics (AAP). He has received many awards including the Brigid Leventhal Special Merit Award through ASCO, and he has been awarded a prestigious K12 from the NCI for the training of the next generation of physician-scientists in pediatric cancer.</p><p>He is board certified in Pediatric Hematology/Oncology and General Pediatrics.</p>

Is Open Scheduling

Off

Jacqueline Weingarten-Arams

https://assets.montefioreeinstein.org/profiles/images/physphoto/Weingarten_Jacqueline_MD_420x504.jpg

First Name

Jacqueline

Last Name

Weingarten-Arams

NPI

1558447409

Faculty ID

4831

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Areas

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

Lab Website Link

EMR ID

3961

Biography

<p>Jacqueline Weingarten-Arams, MD, is an attending physician and Professor, Pediatrics at Montefiore Einstein. Dr. Weingarten-Arams&rsquo; pediatric critical care expertise focuses on cardiac critical care, acute hypoxemic respiratory failure, nutrition in critical illness and energy expenditure, cardiopulmonary resuscitation (quality CPR) and extracorporeal life support (ECMO).</p><p>After obtaining her Bachelor of Science in nutritional biochemistry at Cornell University in 1982, Dr. Weingarten-Arams earned her Doctor of Medicine at the same institution in 1986. She then completed her pediatric residency at Columbia University in 1990, where she was Chief Resident in her final year. Following this, Dr. Weingarten-Arams completed a fellowship in pediatric critical care medicine at New York Hospital Cornell University Medical College in 1996.</p><p>Dr. Weingarten-Arams research focus includes the use of deliberate simulated practice in improving outcomes in pediatric critical illness, pediatric resuscitation and pediatric airway management. Her other projects involve chronic critical illness, bioethics in pediatric critical care and oxidative injury in respiratory failure. She has been principal investigator and co-investigator on several research projects, and her work has been shared through numerous peer-reviewed publications and invited presentations.</p><p>Dr. Weingarten-Arams is a Diplomate of the National Board of Medical Examiners and the American Board of Pediatrics. She is a Fellow of the American Academy of Pediatrics and the American College of Chest Physicians. She is also a member of several professional organizations, including the American Medical Association, the Pediatric Cardiac Intensive Care Society and the Society of Critical Care Medicine. Dr. Weingarten-Arams has been named in Castle Connolly&rsquo;s &ldquo;Top Doctors: New York Metro Area&rdquo; for multiple years. In 2006, she was inducted into the Leo M. Davidoff Society and in 2019, Dr. Weingarten-Arams won the William Obrinsky Award for Excellence in Medical Student Education.</p>

Is Open Scheduling

Off

Shudan Wang

https://assets.montefioreeinstein.org/profiles/images/physphoto/Wang_Shudan_420x504.jpg

First Name

Shudan

Last Name

Wang

NPI

1831432780

Faculty ID

15876

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; text-indent: .5in; line-height: normal;"><span style="font-size: 12.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: 'Times New Roman';">Dr. Wang is an Attending Physician in the Division of Rheumatology at Montefiore Medical Center, and an Assistant Professor of Medicine at Albert Einstein College of Medicine. She is board certified in both internal medicine and rheumatology and currently sees patients at the Montefiore Westchester Practice at Taxter Road. Dr. Wang has an expertise in lupus and lupus related kidney disease. She is also skilled to see a wide range of other rheumatologic diseases, including but not limited to antiphospholipid syndrome, Sjogren&rsquo;s syndrome, rheumatoid arthritis, <span style="color: black;">spondyloarthropathy</span>&nbsp;and psoriatic arthritis, vasculitis, myositis, polymyalgia rheumatica, scleroderma and osteoarthritis.</span></p>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; text-indent: .5in; line-height: normal;"><span style="font-size: 12.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: 'Times New Roman';">Dr. Wang graduated from McGill University with a major in Physiology and Statistics in 2009. Dr. Wang received her medical degree from Rutgers New Jersey Medical School in 2013. She subsequently completed her internal medicine residency training at New York Presbyterian Hospital Cornell in 2016, followed by a fellowship in Rheumatology at New York University Hospital in 2018. Dr. Wang obtained a MS in clinical research from the Albert Einstein Clinical Research Training Program in 2021. </span></p>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; text-indent: .5in; line-height: normal;"><span style="font-size: 12.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: 'Times New Roman';">Dr. Wang's research interest is in lupus, focused on the role of the complement system in lupus related kidney disease. Dr. Wang is supported by the NIH KL2 Mentored Clinical Research Scholar Grant and the Rheumatology Research Foundation K-Bridge Grant to investigate complement biomarkers in lupus nephritis using various translational approaches including immunohistochemistry, urine proteomics and single cell RNA sequencing. Dr. Wang has experience working with large cohorts and databases, recruiting patients for the Einstein Rheumatic Disease Registry and serve as sub-investigator for lupus clinical trials. She has published first author papers in prestigious journals, presented her academic work at national meetings and served on NIH and CDC study sections. She was recognized by American College of Rheumatology as a Distinguished Fellow nationally for translational research and clinical excellence in 2018.</span></p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p class="MsoNormal" style="mso-outline-level: 1;"><strong><span style="font-family: 'Arial',sans-serif;">Wang Shudan</span></strong><span style="font-family: 'Arial',sans-serif;">, Wu M, Chiriboga L, Zeck B, Goilav B, Wang Shuwei, Jimenez-Londono A, </span><span style="font-family: 'Arial',sans-serif;">Putterman C, Schwartz D, Pullman J, Broder A, HM Belmont. Membrane Attack Complex (MAC) Deposition in Renal Tubules is Associated with Interstitial Fibrosis/Tubular Atrophy: A Pilot Study. <em>Lupus Science &amp; Medicine. </em>2022 Jan; 9(1). </span></p>
<p class="MsoNormal" style="mso-outline-level: 1;"><span style="font-family: 'Arial',sans-serif;">Tagoe, CE, Wang W, <strong>Wang S</strong>, Barbour K. Association of anti-thyroid antibodies with radiographic knee osteoarthritis and chondrocalcinosis: a NHANES III study. <em>Therapeutic Advances in Musculoskeletal Disease. </em>2021 Aug 4; 13. </span></p>
<p class="MsoNormal" style="mso-outline-level: 1;"><span style="font-family: 'Arial',sans-serif;">Guerrero, MS, Londono, A, Dobrowolski C, Mowrey WB, Goilav B, <strong>Wang S</strong>, Broder A. Systemic Lupus Erythematosus Activity and Hydroxychloroquine Use Before and After End-Stage Renal Disease. <em>BMC Nephrology</em>. 2020 Oct 28; 21(1): 450.</span></p>
<p class="MsoNormal"><strong style="mso-bidi-font-weight: normal;"><span style="font-family: 'Arial',sans-serif;">Wang S, </span></strong><span style="font-family: 'Arial',sans-serif;">Wu M, Pillinger MH, Krasnokutsky, S, and Barbour K. The Association between Asymptomatic Hyperuricemia and Knee Osteoarthritis: Data from Third National Health and Nutrition Examination Survey. <a title="Osteoarthritis and cartilage." href="https://www.ncbi.nlm.nih.gov/pubmed/?term=The+Association+between+Asymp… class="highlight"><em><span style="color: windowtext; text-decoration: none; text-underline: none;">Osteoarthritis</span></em></span><em> Cartilage.</em></a> 2019 Sep;27(9):1301-1308. </span></p>
<p class="MsoNormal"><strong style="mso-bidi-font-weight: normal;"><span style="font-family: 'Arial',sans-serif; color: black;">Wang S, </span></strong><span style="font-family: 'Arial',sans-serif; color: black;">Wu M, Chiriboga L, Zeck B, HM Belmont. Membrane Attack Complex (MAC) Deposition in Lupus Nephritis is Associated with Hypertension and Poor Clinical Response to Treatment. <em style="mso-bidi-font-style: normal;">Semin Arthritis Rheum. 2018; 48(2): 256-262.</em><span style="mso-spacerun: yes;">&nbsp; </span></span></p>
<p class="MsoNormal"><strong style="mso-bidi-font-weight: normal;"><span style="font-family: 'Arial',sans-serif; color: black;">Wang S, </span></strong><span style="font-family: 'Arial',sans-serif; color: black;">Broder N, Marchetta P, Nowatzky J. Myelodysplastic syndrome presenting as a Behcet&rsquo;s like syndrome with aortitis. <em style="mso-bidi-font-style: normal;">BMJ Case Rep. 2018 March 15. </em><span style="mso-spacerun: yes;">&nbsp;</span></span></p>
<p class="MsoNormal"><span style="font-family: 'Arial',sans-serif; color: black;">Oshima-Takane Y, <strong style="mso-bidi-font-weight: normal;">Wang S</strong>, Takane M and Takane, Y. T</span><span style="font-family: 'Arial',sans-serif;">he Acquisition of Personal Pronouns in English: Neural Network Stimulations. S<em style="mso-bidi-font-style: normal;">tudies in Language Sciences. 2014, Jan: 13 (53-69).</em></span></p>
<p class="MsoNormal" style="margin-right: 24.0pt;"><span style="font-family: 'Arial',sans-serif;">Sleat DE, Ding L, <strong style="mso-bidi-font-weight: normal;">Wang S, </strong>Zhao C, Wang Y, Zheng H, Moore DF, Sims KB, Lobel P<strong style="mso-bidi-font-weight: normal;">. </strong>Mass spectrometry-based protein profiling to determine the cause of lysosomal storage disease of unknown etiology. <em style="mso-bidi-font-style: normal;">Mole Cell Proteomics</em>. <em style="mso-bidi-font-style: normal;">2009 Jul; 8(7): 1708-18.</em> </span></p>
<p class="MsoNormal" style="margin-right: 24.0pt; text-indent: -.25in;"><strong style="mso-bidi-font-weight: normal;"><span style="mso-bidi-font-family: Arial;">&nbsp;</span></strong></p>

EMR ID

13915

Visit Type ID

2528

Is Open Scheduling

On

Zocdoc Link

Berrin Ustun

https://assets.montefioreeinstein.org/profiles/images/physphoto/Ustun_Berrin_MD_11119532.jpg

First Name

Berrin

Last Name

Ustun

NPI

1568789394

Faculty ID

13617

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5648

Is Open Scheduling

Off

Henry Michael Ushay

https://assets.montefioreeinstein.org/profiles/images/physphoto/Ushay_Michael_MD_420x504.jpg

First Name

Henry

Last Name

Ushay

NPI

1558332007

Faculty ID

10275

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

Pediatric critical care medicine with a special emphasis on respiratory failure; shock resuscitation; cardiac intensive care; intensive care of pediatric oncology patients; extracorporeal support for children with respiratory and cardiovascular failure

Research Focus

Leadership and direction of the 16-bed Pediatric Critical Care Unit of The Children&rsquo;s Hospital at Montefiore; improving medication safety; respiratory physiology; advances in the management of respiratory failure in children; shock; medical ethics

Elsevier Profile

EMR ID

4763

Biography

<p>Dr. Ushay is Professor of Clinical Pediatrics in the Albert Einstein College of Medicine. He is a Fellow of the American Academy of Pediatrics as well as a Fellow of the American College of Critical Care Medicine. </p><p>After obtaining a PhD in Chemistry from Columbia University, Dr. Ushay received his MD from UMDNJ-New Jersey Medical School and completed a Pediatrics residency in the Montefiore-Jacobi-Einstein program. After serving as Chief Resident and a Fellow in Pediatric Pulmonology at Montefiore, he completed a Pediatric Critical Care Fellowship at New York Hospital/Cornell Medical Center in 1993. He was a faculty member at NewYork-Presbyterian and Memorial Sloan-Kettering Hospitals from 1993 to 2005, and he served as Pediatric Critical Care Medicine Fellowship Program Director and Medical Director of the Pediatric Observation Unit at Memorial Sloan-Kettering Cancer Center. </p><p>In 2005 Dr. Ushay became Director of the Pediatric Critical Care Unit in The Children&rsquo;s Hospital at Montefiore. Dr. Ushay is involved in increasing pediatric ICU surge capacity through the New York City Pediatric Disaster Coalition, serving on its Central Leadership Council and teaching the Pediatric Fundamental Critical Care Support Course. Through the National Institute of Child Health and Human Development, Dr. Ushay works on employing medical countermeasures safely for children in the event of chemical, biological or radiological disaster. Sponsored by Surgeons of Hope and Children&rsquo;s HeartLink, Dr. Ushay has worked as a cardiac intensivist in Cambodia, Africa, China and Nicaragua. </p>

Is Open Scheduling

Off

Clement E. Tagoe

https://assets.montefioreeinstein.org/profiles/images/physphoto/Tagoe_Clement_MD_420x504.jpg

First Name

Clement

Last Name

Tagoe

NPI

1801985197

Faculty ID

9904

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Clement Tagoe obtained his medical degree from the University of Ghana Medical School, Ghana, and a PhD in biochemistry from the University of Leeds, UK. His basic science research interests included the study of the role of annexins in cell function and rheumatic diseases, and subsequently the mechanisms of disease in transthyretin amyloidosis using several animal models of transthyretin amyloidosis. His clinical work in the area of transthyretin amyloidosis has greatly illuminated our understanding of the form of amyloidosis associated with the Transthyretin V122I (pV142I) mutation, which is found in about 3 to 4% of African Americans. His current work focuses on the role of autoimmune diseases in fibromyalgia and chronic widespread pain, and in particular the association of these syndromes with autoimmune thyroid disease (AITD). His work also explores the other musculoskeletal and rheumatic manifestations of autoimmune thyroid disease, including the association with peripheral osteoarthritis and spinal osteoarthritis. These autoimmune syndromes can occur in the absence of thyroid dysfunction and are of particular interest to physicians and patients because AITD is by far the commonest autoimmune disease.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p class="MsoNormal"><strong>Selected Bibliography</strong></p>
<p class="MsoNormal">1. Clement E. Tagoe, Tejas Sheth, Eugeniya Golub, Karen Sorensen (2019) Rheumatic associations of autoimmune thyroid disease: a systematic review Clin Rheumatol. 2019 Jul;38(7):1801-1809., (1-9) DOI:&nbsp; 10.1007/s10067-019-04498-1</p>
<p class="MsoNormal">2. Kavisha Patel, Clement Tagoe, Phyllis Bieri, Karen Weidenheim &amp; James M. Tauras (2018): A case of transthyretin amyloidosis with myopathy, neuropathy, and cardiomyopathy resulting from an exceedingly rare mutation transthyretin Ala120Ser (c.418G &gt; T, p.Ala140Ser), Amyloid, DOI: 10.1080/13506129.2018.1491398</p>
<p class="MsoNormal">3. Daniel R. Jacobson, Alice A. Alexander, Clement Tagoe, W. Timothy Garvey, Scott M.</p>
<p class="MsoNormal">Williams, Sara Tishkoff, David Modiano, Sodiomon Bienvenu Sirima, Issa Kalidi, Toure A, &amp; Joel N. Buxbaum. The Prevalence and Distribution of the Amyloidogenic Transthyretin (TTR) V122I Allele in Africa&nbsp; Molecular Genetics &amp; Genomic Medicine Epub 14 July, 2016&nbsp; DOI: 10.1002/mgg3.231</p>
<p class="MsoNormal">4. Asha Shrestha, Hillel W. Cohen, Clement E. Tagoe. Association of Autoimmune Thyroid Disease With A Higher Frequency Of Spinal Degenerative Disc Disease Clin Exp Rheumatol. 2016 Mar-Apr;34(2):296-302. Epub 2016 Feb 9. PMID: 26885680</p>
<p class="MsoNormal">5. Tagoe CE, Zezon A, Khattri S. Rheumatic manifestations of autoimmune thyroid disease: the other autoimmune disease. J Rheumatol. 2012 Jun;39(6):1125-9. Epub 2012 Apr 15.</p>
<p>&nbsp;</p>
<p class="MsoNormal">&nbsp;</p>
<p>&nbsp;</p>

EMR ID

4680

Visit Type ID

2528

Is Open Scheduling

On